Lumibird SA (EPA:LBIRD)
France
· Delayed Price · Currency is EUR 23.10
-0.60 (-2.53%)
At close: Mar 9, 2026
Lumibird Revenue
Lumibird had revenue of 108.28M EUR in the half year ending June 30, 2025, with 9.97% growth. This brings the company's revenue in the last twelve months to 219.10M, up 5.67% year-over-year. In the year 2024, Lumibird had annual revenue of 210.06M with 1.70% growth.
Revenue (ttm)
219.10M
Revenue Growth
+5.67%
P/S Ratio
2.32
Revenue / Employee
205.15K
Employees
1,068
Market Cap
508.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 210.06M | 3.50M | 1.70% |
| Dec 31, 2023 | 206.55M | 12.26M | 6.31% |
| Dec 31, 2022 | 194.29M | 27.91M | 16.77% |
| Dec 31, 2021 | 166.39M | 36.88M | 28.48% |
| Dec 31, 2020 | 129.51M | 16.85M | 14.96% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 28.49B |
| Sanofi | 46.72B |
| Sartorius Stedim Biotech | 2.97B |
| Ipsen | 3.93B |
| Inventiva | 16.97M |
| Vetoquinol | 532.39M |
| Valneva SE | 179.91M |
| MedinCell | 32.44M |